TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...ted-Anticancer-Therapies/Why-is-PI3K-so-hard

Hyperactivation of the PI3K-AKT-mTOR signaling cascade occurs in a plethora of cancer types. Both preclinical data and clinical studies suggest that this pathway is a valid pharmacological target in selected patient populations.

Date: 07 Mar 2018
Presenter: Maurizio Scaltriti
Resources: Abstract, Presentation

https://oncologypro.esmo.org/Meeting-Resour...T-inhibitors-and-other-new-kids-on-the-block

Date: 07 Mar 2018
Presenter: Lillian Siu
Resources: Abstract
Topics: Translational Research, Biomarkers

https://oncologypro.esmo.org/Meeting-Resour...tors-to-the-treatment-cocktail-alter-outcome

The PI3K/AKT/mTOR pathway (PI3K pathway) is an important cell signaling pathway in cancer, identified as important in cell growth regulation, proliferation and survival.

Date: 07 Mar 2018
Presenter: Patricia Lorusso
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ncer-Therapies/Other-uses-of-PI3K-inhibitors

Most solid tumours demonstrate genetic activation of the PI3K pathway. However, the clinical impact of PI3K-inhibitors, aimed at dampening cancer-cell-intrinsic PI3K activity, has been limited.

Date: 07 Mar 2018
Presenter: Bart Vanhaesebroeck
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...AVID100-an-anti-EGFR-antibody-drug-conjugate

AVID100, an anti-EGFR-DM1 conjugate, showed potent activity in preclinical models in vitro and in vivo including in cell lines resistant to approved anti-EGFR mAbs.

Date: 07 Mar 2018
Presenter: Anthony Tolcher
Resources: Abstract
Topic: Anti-Cancer Agents & Biologic Therapy